Sihe Zhang | Pharmacology | Best Researcher Award

Prof Sihe Zhang | Pharmacology | Best Researcher Award

Professor at  Nankai University, China

Si-he Zhang is a distinguished cell biologist and professor at Nankai University, China. He earned his PhD in Cell Biology from the Fourth Military Medical University and has held various academic positions including Associate Professor at Lund University Hospital, Sweden. His research focuses on cancer biology, particularly in developing targeted therapies using antibodies and nanoparticle-based drug delivery systems. Zhang has authored numerous influential publications and holds several key patents in the field. He has received prestigious awards, including the Chinese Outstanding Patented Invention Gold Award and the National Prize for Progress in Science & Technology. Zhang also serves on several scholarly committees and as a consultant for leading biopharmaceutical companies in China.

Profile

Scopus

Education:

  • PhD in Cell Biology, Fourth Military Medical University, China, 2001-2004
  • M.A. in Genetics, Jinlin University, China, 1996-1998
  • B.S. in Genetics, Northwest A&F University, China, 1991-1995

Positions Held:

  • Tenured Full Professor, Nankai University, China (2020-present)
  • Tenured Associate Professor, Nankai University, China (2012-2019)
  • Postdoctoral Scientist, Lund University Hospital, Sweden (2006-2009)
  • Associate Professor, Fourth Military Medical University, China (2005-2011)
  • Lecturer, Fourth Military Medical University, China (2000-2005)
  • Teaching Assistant, Fourth Military Medical University, China (1998-2000)

Major Awards:

  • Gold Award for Chinese Outstanding Patented Invention, WIPO-SIPO (2010)
  • National Prize for Progress in Science & Technology, China (2005)

Citations:

  • Citations: 948
  • Documents Contributed: 43
  • h-index: 15

Publications Top Notes

  • Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity
    • Qi, F.-Z., Su, H.-S., Wang, B., …, Chen, Z.-N., Zhang, S.-H.
    • MedComm, 2024, 5(3), e512
  • Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy
    • Song, N., Sun, Z., Wang, B., …, Zhang, S., Yu, Z.
    • Acta Biomaterialia, 2024, 175, pp. 250–261
  • Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma
    • Ye, Z., Wang, Y., Yuan, R., …, Qian, L., Zhang, S.
    • Journal of Cancer, 2024, 15(12), pp. 3645–3662
  • Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma
    • Wang, B., Qi, F.-Z., Chen, P., …, Chen, Z.-S., Zhang, S.-H.
    • International Journal of Biological Sciences, 2024, 20(5), pp. 1634–1651
  • Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress
    • Sun, Z., Huang, J., Fishelson, Z., Wang, C., Zhang, S.
    • Biomedicines, 2023, 11(7), 1971
  • GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer
    • Su, L., Sun, Z., Qi, F., …, Chen, Z., Zhang, S.
    • Journal of Nanobiotechnology, 2022, 20(1), 340
  • Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC
    • Zhang, Q., Liu, X., Chen, Z., Zhang, S.
    • Frontiers in Pharmacology, 2022, 13, 937531